The global computational biology market was valued at $5,493.2 million in 2021, and is projected to reach $31,477.1 million by 2031, registering a CAGR of 19.5% from 2022 to 2031.
Computational biology is the inter-disciplinary applied science, which utilizes concepts of basic biology through the use of mathematical, theoretical, and computer simulation models to study biological systems, structures, and processes of life.. It entails the use of computational methods (e.g., algorithms) for the representation and simulation of biological systems as well as for the interpretation of experimental data, often on a very large scale.
The sequence and structural similarities of an unknown and a known protein as well as the proteins’ interactions with other molecules are used to make functional predictions. As such analyses can be lengthy, the demand for computational biology has increased rapidly., Therefore, these analyses guide the process of building 3D models of the target protein structure, which are then refined, ranked, and compared with one another to select the final predictions.. Biochemical, regulatory, and genetic pathways are highly branched and interleaved, as well as dynamic, necessitating the use of advanced computational methods to model and analyze them.
The COVID-19 pandemic has had an impact on the computational biology market. To curb the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.
Furthermore, the outbreak of COVID-19 led to high mortality, high contagion rate, and a lack of clinically approved drugs and vaccines. To find safe and effective therapeutic options to treat this infectious disease, computational biology plays an extremely relevant role to better understand the virus pathogenic mechanism as well as to propose novel therapeutic strategies. Accordingly, due to progress in computer science, in silico methodologies in medicinal chemistry, pharmacology, biology, genetics, and virology cover relevant tasks in modern research in these fields. Furthermore, due to the current global health warning, such computational techniques could speed up research to provide innovative and targeted approaches to fight the coronavirus emergency. Hence, computational biology will help the medical science field irreversibly to find a cure and boost the growth of the pharma market.
The growth of the global computational biology market is majorly driven by rise in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics for better understanding of protein structure and interactions.. In addition, factors fueling the market growth include rise in R&D activities for drug discovery, surge in demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding.
The application of sophisticated algorithms and statistical models in computational biology to analyze biological data enables researchers to gather critical insights, which can be utilized for discovery of new drugs. Moreover, application of machine learning and artificial intelligence allowed researchers to develop a better understanding of biological systems, discovering new drugs, designing new proteins to cure diseases, and help in understanding genetic code to predict diseases. Several start-ups in computational biology provide software platform that contributes to the pharmaceutical development process. This is expected to contribute to revenue growth of the market.
.
Moreover, increase in demand from the contract research organization for computational biology drives the growth of the market. Contract research organization service providers work with clients to develop a customized plan as per the requirements. For instance, the Bioinformatics CRO, Inc. is a contract research organization that offers bioinformatics services to biotechnology companies worldwide.
The computational biology software/tools help in building custom analytical pipelines to generate more critical insights from data also it can be used to further analyze gene expression data from bulk and single-cell RNA-sequence, and perform network analysis such as Weighted Gene Co-expression Network Analysis (WGCNA). Various sectors such as the pharmaceutical, biotechnology, and medical device use computational biology for developing their products. Thus, rapid development of these sectors notably contributes toward the growth of the global computational biology market.
However, complications such as allergic reactions that cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, high initial cost & maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce act as the key deterrent factors of the global market.
The global computational biology market is segmented into application, service, and end use, and region. By application, the market is segregated into cellular & biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials, and human body simulation software.
The cellular & biological simulation is sub-segmented into computer, genomics, computational proteomics, pharmacogenomics, and others. The drug discovery & disease modeling segregated into target identification, target validation, lead discovery, and lead optimization. The pre-clinical drug development segmented into pharmacokinetics and pharmacodynamics. The clinical trials are subcategorized into phase I, phase II, and phase III.
On the basis of services, the segment is divided into in-house services and contract. On the basis of end use the segment is divided into academics & research and commercials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies that operate in the computational biology market are Altaris Capital Partner, Compugen Ltd., Certara, Genedata AG, Dassault Systems, DNAnexus, Nimbus Discovery, Instem, Rosa & Co. Ltd, and Simulation Plus.
The computational biology market forecast is studied from 2022 to 2031.
The market size and estimations are based on a comprehensive analysis of key developments in the computational biology industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the computational biology market.
Computational biology is the inter-disciplinary applied science, which utilizes concepts of basic biology through the use of mathematical, theoretical, and computer simulation models to study biological systems, structures, and processes of life.. It entails the use of computational methods (e.g., algorithms) for the representation and simulation of biological systems as well as for the interpretation of experimental data, often on a very large scale.
The sequence and structural similarities of an unknown and a known protein as well as the proteins’ interactions with other molecules are used to make functional predictions. As such analyses can be lengthy, the demand for computational biology has increased rapidly., Therefore, these analyses guide the process of building 3D models of the target protein structure, which are then refined, ranked, and compared with one another to select the final predictions.. Biochemical, regulatory, and genetic pathways are highly branched and interleaved, as well as dynamic, necessitating the use of advanced computational methods to model and analyze them.
The COVID-19 pandemic has had an impact on the computational biology market. To curb the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.
Furthermore, the outbreak of COVID-19 led to high mortality, high contagion rate, and a lack of clinically approved drugs and vaccines. To find safe and effective therapeutic options to treat this infectious disease, computational biology plays an extremely relevant role to better understand the virus pathogenic mechanism as well as to propose novel therapeutic strategies. Accordingly, due to progress in computer science, in silico methodologies in medicinal chemistry, pharmacology, biology, genetics, and virology cover relevant tasks in modern research in these fields. Furthermore, due to the current global health warning, such computational techniques could speed up research to provide innovative and targeted approaches to fight the coronavirus emergency. Hence, computational biology will help the medical science field irreversibly to find a cure and boost the growth of the pharma market.
The growth of the global computational biology market is majorly driven by rise in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics for better understanding of protein structure and interactions.. In addition, factors fueling the market growth include rise in R&D activities for drug discovery, surge in demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding.
The application of sophisticated algorithms and statistical models in computational biology to analyze biological data enables researchers to gather critical insights, which can be utilized for discovery of new drugs. Moreover, application of machine learning and artificial intelligence allowed researchers to develop a better understanding of biological systems, discovering new drugs, designing new proteins to cure diseases, and help in understanding genetic code to predict diseases. Several start-ups in computational biology provide software platform that contributes to the pharmaceutical development process. This is expected to contribute to revenue growth of the market.
.
Moreover, increase in demand from the contract research organization for computational biology drives the growth of the market. Contract research organization service providers work with clients to develop a customized plan as per the requirements. For instance, the Bioinformatics CRO, Inc. is a contract research organization that offers bioinformatics services to biotechnology companies worldwide.
The computational biology software/tools help in building custom analytical pipelines to generate more critical insights from data also it can be used to further analyze gene expression data from bulk and single-cell RNA-sequence, and perform network analysis such as Weighted Gene Co-expression Network Analysis (WGCNA). Various sectors such as the pharmaceutical, biotechnology, and medical device use computational biology for developing their products. Thus, rapid development of these sectors notably contributes toward the growth of the global computational biology market.
However, complications such as allergic reactions that cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, high initial cost & maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce act as the key deterrent factors of the global market.
The global computational biology market is segmented into application, service, and end use, and region. By application, the market is segregated into cellular & biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials, and human body simulation software.
The cellular & biological simulation is sub-segmented into computer, genomics, computational proteomics, pharmacogenomics, and others. The drug discovery & disease modeling segregated into target identification, target validation, lead discovery, and lead optimization. The pre-clinical drug development segmented into pharmacokinetics and pharmacodynamics. The clinical trials are subcategorized into phase I, phase II, and phase III.
On the basis of services, the segment is divided into in-house services and contract. On the basis of end use the segment is divided into academics & research and commercials. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies that operate in the computational biology market are Altaris Capital Partner, Compugen Ltd., Certara, Genedata AG, Dassault Systems, DNAnexus, Nimbus Discovery, Instem, Rosa & Co. Ltd, and Simulation Plus.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current computational biology market trends from 2022 to 2031 to identify the prevailing opportunities along with the strategic assessment.The computational biology market forecast is studied from 2022 to 2031.
The market size and estimations are based on a comprehensive analysis of key developments in the computational biology industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the computational biology market.
Key Market Segments
By Application
- Cellular Biological Simulation
- Drug Discovery Disease Modelling
- Preclinical Drug Development
- Clinical Trials
- Human Body Simulation Software
By Services
- Contract
- In-house
By End Use
- Academics Research
- Commercial
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Chemical Computing Group Inc.
- Compugen Ltd.
- Simulation Plus Inc.
- Genedata AG
- Certara
- Insilico Biotechnology AG
- Accelrys
- Rhenovia Pharma SAS
- Entelos
- Nimbus Discovery LLC
- Rhenovia Pharma SAS & Leadscope Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: COMPUTATIONAL BIOLOGY MARKET, BY APPLICATION
CHAPTER 5: COMPUTATIONAL BIOLOGY MARKET, BY SERVICES
CHAPTER 6: COMPUTATIONAL BIOLOGY MARKET, BY END USE
CHAPTER 7: COMPUTATIONAL BIOLOGY MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Computational Biology Market," the computational biology market size was valued at $5.5 billion in 2021, and is estimated to reach $31.5 billion by 2031, growing at a CAGR of 19.5% from 2022 to 2031.Computational bio-modeling uses computer-aided biological models to generalize methods and properly depict simulations in virtual space to review difficulties in biological models. Computational genetics is a branch of computational biology that studies genomic homology and internal biological systems through genome sequencing. One of the most notable examples is the Human Genome Project, which successfully sequenced the whole human genome.
Computational biology is used in neurology to see and comprehend three-dimensional simulation models of the brain by mapping complicated interconnected pathways. In the drug development process, computational pharmacology makes use of computer-aided visualization techniques to simulate advanced drug-drug interactions. Epidemiological studies have serious limits in terms of demonstrating a cause-and-effect relationship, whereas laboratory research is designed to accomplish so.
Factors that drive growth of the computational biology market share include increase in R&D activities for drug discovery, demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding. For instance, in March 2019, Ambrx Inc., a clinical-stage biopharmaceutical company focused in the field of protein therapeutics, signed R&D collaboration with BeiGene, Ltd., a commercial stage pharmaceutical company involved in the development of immuno-oncology drugs. Ambrx has proprietary Expanded Genetic Code platform designed to incorporate a non-natural amino acid into protein sequences of both E-coli and Chinese Hamster Ovary (CHO) cells. With this collaboration, both will leverage Ambrx’s drug discovery platforms with the latter’s knowledge expertise and resource pool for the development of clinically advanced biologics drugs.
Increase in number of key players to launch various computational biology products and rise in number approvals for computational biology products notably contributed toward the market growth. For instance, in May 2021, Certara, Inc., the world leader in bio-simulation, released new versions of its quantitative systems pharmacology (QSP) simulators for immunogenicity (IG) and immuno-oncology (IO) to aid in the development of biologics and cancer treatments.
Moreover, in March 2021, Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, published a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis," which looks at the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy.
The global computational biology market growth is segmented into application, service, end use, and region. On the basis of application, the market is categorized into cellular & biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials, and human body simulation software.
The cellular & biological simulation is sub-segmented into computer, genomics, computational proteomics, pharmacogenomics, and others. The drug discovery & disease modeling segregated into target identification, target validation, lead discovery, and lead optimization. The pre-clinical drug development segmented into pharmacokinetics and pharmacodynamics. The clinical trials are subcategorized into phase I, phase II, and phase III.
Depending on service, the segment is bifurcated into in-house services and contract. By end use, it is fragmented into academics & research and commercials.
Region wise, the computational biology industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for a majority share of the computational biology market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed due to surge in demand for tools of computational biology in various fields such as genomics, epi-genomics, proteomics, and meta-genomics for better understanding of protein structure & interaction; increase in number of approvals for computational biology products; strong presence of key players; and advancement in healthcare & medical device in the region. however, Asia-Pacific is anticipated to witness lucrative growth, owing to technological advancements in the field of healthcare.
By application segment, the computational biology market is divided into cellular and biological simulation, drug discovery & disease modeling, pre-clinical drug development, clinical trials and human body simulation software. The cellular & biological simulation segment was the highest revenue contributor to the market. Owing to increase in demand of virtual cells open-source software, computer genomics & computational proteomics also many private and commercial cloud platforms work in collaboration with governmental and public entities to provide cellular & biological simulation service are expected to drive the market growth.
The drug discovery & disease modeling segment is estimated to be the largest growing segment during the computational biology market forecast. Owing to increase in number of drug development and rise in awareness regarding target selection by using various methods such as assay and readers, automation and high content screening.
By services, the contract segment was the highest revenue contributor to the market. This is owing to the fact that contract services are cheap when compared to the in-house services provided worldwide. Contract Research Organization (CRO) pro service providers work with clients to develop a customized plan as per the requirements therefore, act as a driver to boost the growth of the market.
The in-house segment is estimated to be the fastest growing segment. In-house service provides a company with greater control over the execution of in-house tasks, since it is the direct employer-based services also because of the advantages such as cost and time saving.
By end use, the commercial segment was the highest revenue contributor to the market. Due to increasing investment in Research and Development (R&D) in genetic engineering and new drug discovery by public as well as private companies, which contribute in the growing demand for computational biology significantly.
The academics & research segment is fastest growing segment during the forecast period. Owing to increase in drug discovery & disease modeling process for various chronic diseases such as cancer, diabetes, cardiovascular diseases, and respiratory disorders that create demand for this segment also increase in demand for predictive models, usage in population-based sequencing projects such as human genome project, and government funding is contributing in the growth of computational biology market.
Region wise, the computational biology market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the largest shareholder in the computational biology market in 2021. Increase in demand of pharmacovigilance for the pre-clinical drug development and to conduct clinical trials, R&D investments, and supportive government initiatives are the major factors and computational biology market trends that drive growth of the market.
LAMEA is estimated to grow fastest during the forecast period. Rise in number of product approval, increase in number of clinical trials procedures, surge in demand for bioinformatics tools & services emphasis of prominent players in enhancing their presence and high demand for advanced computational biology software in the region.
Some of the key players operating in the global computational biology market include Altaris capital partner, Compugen ltd., Certara, Genedata AG, Dassault systems, DNAnexus, Nimbus discovery, Instem, Rosa & co. ltd, and Simulation Plus
Key Findings of the Study
- By application type, the cellular & biological simulation services segment was the highest contributor to the market in 2021.
- By services, the contract service was the highest contributor to the market in 2021.
- By end use, the academic & research segment is projected to grow at a significant CAGR of 20.2% from 2022 to 2031.
- By region, North America garnered largest revenue share in 2021, whereas LAMEA is anticipated to grow at the highest CAGR of 23.0% during the review period.
Companies Mentioned
- Chemical Computing Group Inc.
- Compugen Ltd.
- Simulation Plus Inc.
- Genedata AG
- Certara
- Insilico Biotechnology AG
- Accelrys
- Rhenovia Pharma Sas
- Entelos
- Nimbus Discovery LLC
- Rhenovia Pharma Sas & Leadscope Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 269 |
| Published | June 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 5493.2 million |
| Forecasted Market Value ( USD | $ 31477.1 million |
| Compound Annual Growth Rate | 19.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
